Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Fineline Cube Jul 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Fineline Cube Jul 8, 2026
Company Drug

AstraZeneca’s Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study

Fineline Cube Nov 27, 2024

UK-based pharmaceutical giant AstraZeneca Inc., (AZ, NASDAQ: AZN) has announced that its Phase III CAPItello-281...

Company Drug

Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA

Fineline Cube Nov 27, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...

Company Drug

J&J’s Stelara Faces New Biosimilar Competition in China with CSPC Pharmaceutical’s Entry

Fineline Cube Nov 27, 2024

Johnson & Johnson (J&J, NYSE: JNJ)’s auto-immune disease drug Stelara (ustekinumab) is set to encounter...

Company Deals Policy / Regulatory

AstraZeneca’s ALXN1850 (Efzimfotase Alfa) Selected for China’s Rare Disease Care Plan

Fineline Cube Nov 27, 2024

The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s...

Company Drug

Amgen’s MariTide Showcases Significant Weight Loss in Phase II Study

Fineline Cube Nov 27, 2024

US biotechnology company Amgen (NASDAQ: AMGN) has announced positive outcomes from the double-blind, dose-ranging Phase...

Company Deals

VectorBuilder and Zhejiang Dapu Biotechnology Form Partnership to Advance Biotech Innovation

Fineline Cube Nov 27, 2024

China-based gene delivery technology developer VectorBuilder has entered into a partnership with Zhejiang Dapu Biotechnology...

Company Drug

Roche’s SKYSCRAPER-01 Study: Tiragolumab-Tecentriq Combo Misses Primary Endpoint in NSCLC

Fineline Cube Nov 27, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has reported an update on the phase III SKYSCRAPER-01...

Company Deals

Roche to Acquire Poseida Therapeutics in a USD 1.5 Billion Deal

Fineline Cube Nov 26, 2024

US-based clinical-stage biopharmaceutical company, Poseida Therapeutics (NASDAQ: PSTX), which specializes in donor-derived CAR-T cell therapies,...

Company Medical Device

Zymeworks and Jazz Pharmaceuticals’ Ziihera Gets Green Light for HER2+ BTC Treatment

Fineline Cube Nov 26, 2024

Partners Zymeworks Inc. (NASDAQ: ZYME) and Jazz Pharmaceuticals, Inc. have received accelerated approval from the...

Company Deals

Lakeside Holding’s Hupan Pharmaceutical Partners with Sinopharm Group Hubei for Supply Chain Services

Fineline Cube Nov 26, 2024

US-based supply chain solution provider Lakeside Holding Limited (NASDAQ: LSH), which specializes in the Asian...

Policy / Regulatory

NHSA to Announce NRDL Adjustment Results at November 28th Press Conference

Fineline Cube Nov 26, 2024

The National Healthcare Security Administration (NHSA) will unveil the results of the negotiation and price...

Policy / Regulatory

NMPA and Local Governments Streamline Drug Approval Processes in China

Fineline Cube Nov 26, 2024

The National Medical Products Administration (NMPA) has released a notification regarding the pilot work for...

Company Deals

Adcendo ApS Secures Oversubscribed USD135 Million Series B Financing to Advance ADC Pipeline

Fineline Cube Nov 26, 2024

Danish antibody drug conjugate (ADC) specialist, Adcendo ApS, has announced the completion of an oversubscribed...

Company Medical Device

Abbott Laboratories Expands Structural Heart Portfolio with TAVI Balloon-Expandable System

Fineline Cube Nov 26, 2024

US-based Abbott Laboratories (NYSE: ABT) has announced the successful application of its transcatheter aortic valve...

Company Drug

Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH

Fineline Cube Nov 26, 2024

US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced positive interim analysis results...

Company Deals

Boston Scientific Corporation to Acquire Intera Oncology Inc., Expanding Cancer Treatment Portfolio

Fineline Cube Nov 26, 2024

US-based medical device giant Boston Scientific Corporation (NYSE: BSX) has announced a definitive acquisition agreement...

Company Drug

Nasal-Phyto Pharmaceutical Receives FDA Clearance for First-Ever Olfactory Drug-Device Combo

Fineline Cube Nov 26, 2024

China-based Nasal-Phyto Pharmaceutical Technology Group Co., Ltd has announced receiving clinical clearance from the US...

Company Drug

GSK’s Blenrep BLA for Multiple Myeloma Treatments Accepted by FDA for Review

Fineline Cube Nov 26, 2024

UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that the US Food and Drug...

Company Drug

Insilico Medicine Gets FDA Approval for Clinical Study of ENPP1 Inhibitor ISM5939

Fineline Cube Nov 26, 2024

China’s generative artificial intelligence (AI)-driven biotech company, Insilico Medicine, has announced that it has received...

Company Drug

SCG Cell Therapy Presents Phase I Data for HBV-Specific TCR-T Therapy SCG101 at AASLD 2024

Fineline Cube Nov 26, 2024

SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has announced...

Posts pagination

1 … 285 286 287 … 692

Recent updates

  • Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement
  • Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721
  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors
  • AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement

Others

Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.